Micafungin: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Candidiasis or aspergillosis treatment: 50-150mg IV daily | *[[Candidiasis]] or [[aspergillosis]] treatment: 50-150mg IV daily | ||
*Antifungal prophylaxis: 1mg/kg IV daily | *Antifungal prophylaxis: 1mg/kg IV daily | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Latest revision as of 10:02, 3 January 2022
Administration
- Type: Antifungal
- Dosage Forms:
- Routes of Administration: Intravenous
- Common Trade Names: Mycamine
Adult Dosing
- Candidiasis or aspergillosis treatment: 50-150mg IV daily
- Antifungal prophylaxis: 1mg/kg IV daily
Pediatric Dosing
- <4mo, <40kg: 2-3mg/kg IV daily
- <4mo, >40kg: 100-150 mg IV daily
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Atrial fibrillation, MI, pericardial effusion, cardiac arrest
- Anemia, hemolysis
- Liver failure, hepatitis
- Encephalopathy
- Intracranial hemorrhage
- Seizure
- Acute renal failure
Common
- Nausea, vomiting, diarrhea
- Headache
- Fever
- Thrombocytopenia
Pharmacology
- Half-life: 5.5-21h
- Metabolism: Hepatic, mostly CYP3A
- Excretion: Mostly fecal
Mechanism of Action
- Inhibits the synthesis of vital fungal cell wall component 1,3 beta-D-glucan